Phthalazine compounds, compositions and methods of use
申请人:Austin Richard J.
公开号:US20090048259A1
公开(公告)日:2009-02-19
The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.
本发明一般涉及在式I中表示的化合物,包括它们的药物组合物以及治疗癌症等疾病或疾病的方法。
PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
申请人:Amgen Inc.
公开号:EP2170866A1
公开(公告)日:2010-04-07
US8153633B2
申请人:——
公开号:US8153633B2
公开(公告)日:2012-04-10
[EN] PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PHTHALAZINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
申请人:AMGEN INC
公开号:WO2009002469A1
公开(公告)日:2008-12-31
[EN] The present invention relates generally to compounds represented in Formula I, pharamaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer. [FR] La présente invention concerne de manière générale des composés représentés par la formule I, des compositions pharmaceutiques contenant ceux-ci et des procédés destinés à traiter des maladies ou des troubles tels que le cancer.
Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists
作者:Brian S. Lucas、Wade Aaron、Songzhu An、Richard J. Austin、Matthew Brown、Hon Chan、Angela Chong、Randall Hungate、Tom Huang、Ben Jiang、Michael G. Johnson、Jacob A. Kaizerman、Gary Lee、Dustin L. McMinn、Jessica Orf、Jay P. Powers、Minqing Rong、Maria M. Toteva、Craig Uyeda、Dineli Wickramasinghe、Guifen Xu、Qiuping Ye、Wendy Zhong
DOI:10.1016/j.bmcl.2010.04.110
日期:2010.6
The Hedgehog (Hh) signaling pathway regulates cell proliferation and differentiation in developing tissues, and abnormal activation of the Hh pathway has been linked to several tumor subsets. As a transducer of Hh signaling, the GPCR-like protein Smoothened (Smo) is a promising target for disruption of unregulated Hh signaling. A series of 1-amino-4-arylphthalazines was developed as potent and orally bioavailable inhibitors of Smo. A representative compound from this class demonstrated significant tumor volume reduction in a mouse medulloblastoma model. (C) 2010 Elsevier Ltd. All rights reserved.